Patients with non-small-cell lung cancer who initially respond to front-line designer therapies but later relapse may soon have another option — a gene-based drug called HKI-272. At 14 centers worldwide, a phase 2 trial led by DF/HCC has been launched to study the impact of this second-line drug
Cancer research gadfly calls for a "Google of science"
You might think that Fortune magazine editor Clifton Leaf would be unwelcome in the mainstream cancer community after his highly critical 2004 cover story, "Why We're Losing the War on Cancer (and How to Win It)."
In that article, Leaf, senior editor-at-large and a cancer survivor, argued that cancer research progress is being oversold to the public, and is being slowed by wrong-headed funding policies by the federal government, insufficient focus on important issues like tumor metastasis, and inefficient clinical trial designs
DF/HCC-UMass Boston partnership to focus on health disparities, cancer research
The Dana-Farber/Harvard Cancer Center (DF/HCC) and the University of Massachusetts Boston have received a five-year, $4.3-million grant from the National Institutes of Health (NIH) to develop a strategy to reduce health disparities in Boston neighborhoods and help further diversify the region’s biomedical leadership through new research and training projects